Current PSA level-20 or above - Page 2 of 5 Posts on Medivizor
Navigation Menu

Current PSA level-20 or above Posts on Medivizor

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Posted by on Mar 5, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of bicalutamide (Casodex) to enzalutamide (Xtandi), both in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The comparison showed that enzalutamide with ADT improves the outcomes particularly in Black men with mHSPC.  Some...

Read More

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Posted by on Jan 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study explored the outcomes of statin (cholesterol-lowering drugs) treatment in patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The authors found that the combination of statins and ADT improved the outcomes of these patients and intermittent ADT (IADT) increased the time...

Read More

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Posted by on Dec 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...

Read More

Searching for patients with advanced prostate cancer to trial a new immune treatment.

Searching for patients with advanced prostate cancer to trial a new immune treatment.

Posted by on Nov 8, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including prostate cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These...

Read More

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of radiotherapy followed by treatment with ipilimumab (Yervoy) in men with metastatic castrate-resistant prostate cancer  (mCRPC). The trial found that this treatment led to higher survival in these patients compared to radiotherapy followed by placebo. Some...

Read More

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Posted by on Aug 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...

Read More

Looking for patients with high-risk prostate cancer to test a combination therapy

Looking for patients with high-risk prostate cancer to test a combination therapy

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This study aims to examine the effectiveness of niraparib (Zejula) combined with hormone therapy and radiotherapy to treat patients with high-risk prostate cancer. The main outcome to be measured will be how long patients remain cancer-free. This study is recruiting in Philadelphia, PA. The details Prostate cancer occurs mostly...

Read More

Looking for men with prostate cancer to test chemotherapy in combination with radiotherapy

Looking for men with prostate cancer to test chemotherapy in combination with radiotherapy

Posted by on Feb 23, 2019 in Prostate cancer | 0 comments

In a nutshell This trial evaluates the effectiveness of using chemotherapy in combination with radium-223 (a type of internal radiotherapy). The main outcome to be measured is overall survival. This trial is taking place in the United States. The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...

Read More